In conclusion, this meta-analysis of patients with heart failure of LVEF>40% showed that SGLT2 inhibitors significantly reduced the risk of the composite of cardiovascular death and hospitalization for heart failure, but not cardiovascular death and all-cause death. Here, SLC5A2 is linked to heart failure.